The structure
Diabetes therapeutics is a very large market by volume and value, with distinct segments: insulins, oral agents, injectable incretins, and the device sector of glucose monitoring and insulin delivery.
The device segment has consolidated, with pump and sensor manufacturers integrating to deliver automated insulin delivery as a system — which changes evaluation, because the product under assessment is a combination of hardware, sensor and algorithm rather than a single component.
What is driving activity
Incretin agents with indications spanning diabetes, obesity, cardiovascular and renal disease, which makes a single molecule relevant across several large populations.
Oral formulations of peptide agents. Biosimilar insulins, which bear on affordability. Software as a medical device, where the algorithm is the regulated product.
The access question
Insulin pricing and access have been the subject of sustained public and political attention, with pricing interventions in some jurisdictions. For a global market, affordability is now a strategic rather than a peripheral consideration.
Evaluating evidence here
Cardiovascular and renal outcome trials in this area are large, long and industry-funded, and they are the evidence base. That is not a reason to discount them, but registration, pre-specified outcomes and independent adjudication of events matter correspondingly more.
For devices and algorithms, check whether the evaluation covers the system as used, including the algorithm version, since results do not transfer across versions.
Separate regulatory approval, reimbursement and guideline recommendation — all three are needed before a therapy reaches patients, and they occur at different times.
In short
What to take from this.
- Device evaluation must name the algorithm version — results do not transfer.
- Large outcome trials here are industry-funded; check registration and adjudication.
- Approval, reimbursement and guideline recommendation are three separate events.
Sources
- Regulatory frameworks for software as a medical device
- Cardiovascular and renal outcome trial literature in diabetes
This page reflects established understanding as at mid-2026 and is not a current-awareness service. Clinical and regulatory positions change; verify anything decision-relevant against a current source.
Related